New microporous cholestyramine analog for treatment of hypercholesterolemia.
A new, microporous, uniformly reticulated preparation of cholestyramine is described. The preparation, cholpor, has a higher exchange capacity for chloride than does cholestyramine and swells very little in water. It is 15--20% more potent than chloestyramine in the in vitro binding of sodium cholate; moreover, the binding velocity is considerably higher than that of cholestyramine. Colestipol hydrochloride, also used as a reference anion-exchange resin, is about half as potent as the other two resins; its binding velocity is similar to that of cholpor. Cholpor may be prepared in a suspension form of good palatability. Preliminary clinical findings in short-term trials showed a cholesterol-lowering effect similar to that of cholestyramine with lower doses and fewer side effects.
D000328:Adult; D000368:Aged; D002792:Cholestyramine Resin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D002793:Cholic Acids / Q000378:metabolism; D003084:Colestipol / Q000378:metabolism; D003248:Constipation / Q000139:chemically induced; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013535:Suspensions
D002793:Cholic Acids; D013535:Suspensions; D002792:Cholestyramine Resin; D003084:Colestipol